310 related articles for article (PubMed ID: 25815442)
1. Overexpression of Tyro3 receptor tyrosine kinase leads to the acquisition of taxol resistance in ovarian cancer cells.
Lee C
Mol Med Rep; 2015 Jul; 12(1):1485-92. PubMed ID: 25815442
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells.
Suh YA; Jo SY; Lee HY; Lee C
Int J Oncol; 2015 Mar; 46(3):1405-11. PubMed ID: 25544427
[TBL] [Abstract][Full Text] [Related]
3. Metformin targets Axl and Tyro3 receptor tyrosine kinases to inhibit cell proliferation and overcome chemoresistance in ovarian cancer cells.
Kim NY; Lee HY; Lee C
Int J Oncol; 2015 Jul; 47(1):353-60. PubMed ID: 25975389
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway.
Li Y; Chen K; Li L; Li R; Zhang J; Ren W
Tumour Biol; 2015 Dec; 36(12):9823-8. PubMed ID: 26159849
[TBL] [Abstract][Full Text] [Related]
5. [Effects of siltuximab on the interleukin-6/Stat3 signaling pathway in ovarian cancer].
Guo YQ; Lu P; Duan ZF; Zhang Z
Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):854-9. PubMed ID: 21211286
[TBL] [Abstract][Full Text] [Related]
6. Caveolin-1 mediates chemoresistance in cisplatin-resistant ovarian cancer cells by targeting apoptosis through the Notch-1/Akt/NF-κB pathway.
Zou W; Ma X; Hua W; Chen B; Cai G
Oncol Rep; 2015 Dec; 34(6):3256-63. PubMed ID: 26503358
[TBL] [Abstract][Full Text] [Related]
7. TLR4 and NFκB signaling is critical for taxol resistance in ovarian carcinoma cells.
Sun NK; Huang SL; Chang TC; Chao CC
J Cell Physiol; 2018 Mar; 233(3):2489-2501. PubMed ID: 28771725
[TBL] [Abstract][Full Text] [Related]
8. [The selection of taxol resistance associated genes in ovarian cancer cell line by mRNA DD].
Cheng G; Tian F; Li Y
Zhonghua Yi Xue Za Zhi; 2000 Jul; 80(7):541-3. PubMed ID: 11798816
[TBL] [Abstract][Full Text] [Related]
9. Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations.
Yan XD; Li M; Yuan Y; Mao N; Pan LY
Oncol Rep; 2007 May; 17(5):1163-9. PubMed ID: 17390060
[TBL] [Abstract][Full Text] [Related]
10. Reversing drug resistance in the ovarian carcinoma cell line SKOV3/mdr1 in vitro by antisense oligodeoxynucleotides.
Pan L; Tong Y; Jin Y; Zhou S; Zhang Y; Yang X; Mao N
Chin Med J (Engl); 2001 Sep; 114(9):929-32. PubMed ID: 11780384
[TBL] [Abstract][Full Text] [Related]
11. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
12. Cepharanthine hydrochloride reverses P‑glycoprotein-mediated multidrug resistance in human ovarian carcinoma A2780/Taxol cells by inhibiting the PI3K/Akt signaling pathway.
Huang CZ; Wang YF; Zhang Y; Peng YM; Liu YX; Ma F; Jiang JH; Wang QD
Oncol Rep; 2017 Oct; 38(4):2558-2564. PubMed ID: 28791369
[TBL] [Abstract][Full Text] [Related]
13. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
14. A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer.
Ishibashi M; Nakayama K; Yeasmin S; Katagiri A; Iida K; Nakayama N; Fukumoto M; Miyazaki K
Clin Cancer Res; 2008 May; 14(10):3149-55. PubMed ID: 18483383
[TBL] [Abstract][Full Text] [Related]
15. [Reversal effect of PI-3K/Akt pathway inhibitor LY294002 on multidrug resistance of ovarian cancer cell line A2780/Taxol].
Shi XY; Cai XJ; Lei JX; Cao FJ; Pan DF; Chen P
Ai Zheng; 2008 Apr; 27(4):343-7. PubMed ID: 18423117
[TBL] [Abstract][Full Text] [Related]
16. Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFκB pathway.
Yang YI; Lee KT; Park HJ; Kim TJ; Choi YS; Shih IeM; Choi JH
Carcinogenesis; 2012 Dec; 33(12):2488-98. PubMed ID: 23027625
[TBL] [Abstract][Full Text] [Related]
17. ERp57‑small interfering RNA silencing can enhance the sensitivity of drug‑resistant human ovarian cancer cells to paclitaxel.
Li S; Zhao X; Chang S; Li Y; Guo M; Guan Y
Int J Oncol; 2019 Jan; 54(1):249-260. PubMed ID: 30431082
[TBL] [Abstract][Full Text] [Related]
18. Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells.
Kim SH; Juhnn YS; Song YS
Ann N Y Acad Sci; 2007 Jan; 1095():82-9. PubMed ID: 17404021
[TBL] [Abstract][Full Text] [Related]
19. [RNA interference silencing expression of survivin gene and reversing drug resistance of ovarian cancer cell line SKOV3/ADM].
Deng KX; Zhong L; Jiang MX; Wang PL; Chen Y
Zhonghua Fu Chan Ke Za Zhi; 2005 Dec; 40(12):836-9. PubMed ID: 16412331
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of phosphorylated cofilin 1 correlates with taxol resistance in human ovarian cancer in vitro and in vivo.
Li M; Yin J; Mao N; Pan L
Oncol Rep; 2013 Jan; 29(1):58-66. PubMed ID: 23064469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
